EH Group Raises Over CHF5m to Advance Its Zero-Emission Fuel Cell Technology
EH Group Engineering AG (“EH Group”), a developer and manufacturer of innovative low-cost and energy-dense fuel cells, today announced it had raised over CHF5m in Pre-Series A funding. AP Ventures, a significant investor in breakthrough hydrogen technologies, participated in the raise. Proceeds will go towards the installation of EH Group’s own proprietary stack assembly technology as well as to the continued development of the Company’s first commercial fuel cell stack products. EH Group will be looking to raise additional capital in 2022 to finance its progression to commercial-scale roll-out.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220113005438/en/
EH Fuel Cell Stack
Hydrogen fuel cells are increasingly being viewed as an attractive technology to decarbonise large parts of industry, particularly heavy-duty transport. Two key barriers to more widespread adoption of fuel cells are the costs and production scale of fuel cell systems. EH Group has developed proprietary technology to help address both these constraints, with the aim of creating energy dense fuel cells that can be produced at a scale and cost to competitively meet global demand across mobile and stationary applications.
“We are delighted to have a marquee investor in AP Ventures join us on our ambitious journey. Their longstanding pedigree in investing across the hydrogen value chain is second to none. We look forward to capturing synergies and deepening our relationship as we work to accelerate our fuel cell deployments”, says Christopher Brandon at EH Group.
“We are excited to invest in, and support Mardit, Chris and the rest of the team at EH Group. We believe this technology has the potential to be game-changing, and targets two important challenges for making fuel cells and hydrogen, as a global decarbonisation vector, more competitive”, says Andrew Hinkly, Managing Partner at AP Ventures.
About EH Group
Founded in 2017, EH Group is focused on the design and production of its innovative fuel cell technology, across both stationary and mobile applications. Its high-performance fuel cell stacks and systems offer market leading power density. The implementation of a fully automated production process is aimed at widespread deployment of its fuel cell technology for a decarbonised future. EH Group is based in Switzerland. https://www.ehgroup.ch/
About AP Ventures
AP Ventures is headquartered in London and manages venture capital funds with a global mandate to invest in pioneering new technologies and businesses which aim to solve global challenges such as renewable energy integration, resource scarcity and a growing population. AP Ventures has been investing in the hydrogen industry since 2013 and is recognized as a leading venture capital fund across this value chain. AP Ventures manages $395 million of assets on behalf of 12 LPs and presently has a portfolio of 17 technology companies across the hydrogen value chain. AP Ventures is led by Andrew Hinkly (Managing Partner) and Kevin Eggers (Partner). More info at: www.apventures.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For further information contact:
Christopher Brandon, Co-Founder
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station9.12.2022 20:04:00 CET | Press release
RevBio, Inc., announced that anexperiment to study Tetranite®, the company’s regenerative bone adhesive biomaterial, has successfully been initiated onboard the International Space Station (ISS). On Saturday, November 26, 2022, the study materials were launched to the space station on SpaceX’s 26th Commercial Resupply Services (SpaceX CRS-26) mission, sponsored by the ISS National Laboratory. This in vivo research, which will be conducted over the next two months on the ISS, will examine the biomaterial’s ability to regenerate bone when used in a microgravity environment where bone growing conditions and the ability to regenerate new bone tissue is significantly compromised. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005635/en/ RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station. This Experiment will Examine TETRANITE’S Ability to Regenerate Bone under the Condition of
Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials9.12.2022 14:00:00 CET | Press release
Updated results from the TROPION-PanTumor01 phase 1 trial showed datopotamab deruxtecan (Dato-DXd) continued to demonstrate encouraging responses in patients with heavily pretreated metastatic triple negative breast cancer (TNBC) and disease progression following standard treatment. Results were presented today as a poster presentation (Abstract #P6-10-03) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 15% of breast cancers are considered triple negative and are associated with higher disease recurrence and worse prognosis compared to other breast cancer subtypes.1,2 It is estimated that only 12% of patients with metastatic TNBC survive five years after diagnosis and median overall survival is between 12 to 18 months.1,3 In the TNBC cohort of TROPION-PanTumor01 (n=44)
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases9.12.2022 14:00:00 CET | Press release
Takeda(TSE:4502/NYSE:TAK) today announced that it will present 15 company-sponsored abstracts at the 64th American Society of Hematology (ASH) Annual Meeting being held December 10-13, 2022 in New Orleans. Takeda’s latest research focuses on improving long-term outcomes for patients with hematologic diseases. Takeda’s presentations will include oral sessions detailing a three-year update of the Phase 3 OPTIC trial demonstrating the efficacy and safety of ICLUSIG® (ponatinib) in patients with resistant chronic-phase chronic myeloid leukemia (CP-CML), and results from a first-in-human Phase 1/2 study evaluating modakafusp alfa (TAK-573) in patients with relapsed / refractory multiple myeloma. “Our latest research is focused on investigating novel mechanisms of action, as well as optimizing approved treatments to improve long-term outcomes and more deeply understand and address unmet needs for patients across a range of hematologic diseases,” said Awny Farajallah, M.D., Head of Global Med
Tecnotree Advances to Acquire Top AIML Platform - CognitiveScale in North America to further Enhance 5G Use case Penetration9.12.2022 13:23:00 CET | Press release
Tecnotree is a market leader in 5G digital Business Support Systems (BSS), with AI/ML capabilities and multi-cloud extensibility. Tecnotree’s global footprint with over 90 Telecom customers in 70 countries around the world, supports ecosystems of over 1 billion subscribers. Tecnotree is the first Digital Platform Service provider to be Platinum Badge Certified by TM Forum for Real-world Open API standards. The company also provides B2B2X partner ecosystem and fintech services for monetization beyond connectivity across gaming, healthcare, education, and banking. Tecnotree has been recognized by Gartner for revenue management and monetization as well as for customer experience management solutions and enjoys the position of a leading stock on the Helsinki Nasdaq since 2020. CognitiveScale (CS) is United States based pioneer in the space of AI Engineering and provides solutions for scalable enterprise AI development and deployment. CognitiveScale is backed by over 100 granted AI patents
Another Sustainability Award for NTHU9.12.2022 10:00:00 CET | Press release
National Tsing Hua University (NTHU) in Taiwan has been awarded the Taiwan University Sustainability Award for the second year in a row! The Award was announced at the 15th Taiwan Corporate Sustainability Awards (TCSA) recently held by the Taiwan Institute for Sustainable Energy (TAISE). Standing out amongst the 47 participating universities, NTHU was ranked first in the comprehensive evaluation, and in the individual competitions received the University Sustainability Report Gold Award. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221209005001/en/ NTHU president W. John Kao (right) accepting the Taiwan University Sustainability Award from You Si-kun, president of the Legislative Yuan. (Photo: National Tsing Hua University) The judges cited the exemplary way in which NTHU has adopted an innovative approach to integrating classroom learning, campus activities and social service, thereby enriching students’ education and cre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom